Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | Classifying MPNs with molecular genetic markers

Torsten Haferlach • 15 Jun 2019
EHA 2019
Acute Myeloid Leukemia Leukemia

Here, Torsten Haferlach, MD, from the Munich Leukemia Laboratory, Munich, Germany, discusses how discrimination between types of myeloproliferative neoplasms (MPNs) can be achieved with genomic analysis using techniques such as next-generation sequencing (NGS), rather than relying solely on histological analysis. Prof. Haferlach was speaking at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from Torsten Haferlach

3:33
The value of WGS and whole transcriptome sequencing in the diagnosis of hematological malignancies
Torsten Haferlach • 9 Dec 2023
1:52
Implementing AI in hematology and the challenges this will overcome
Torsten Haferlach • 9 Dec 2023
2:57
Why do we need AI in the hematology clinic?
Torsten Haferlach • 9 Dec 2023
1:53
Role of NGS in acute leukemias
Torsten Haferlach • 17 Sep 2020

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals